[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100065601":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":47,"centralContacts":40,"locations":40,"responsibleParty":51,"collaborators":40,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":40,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":40,"enrollmentInfo":63,"targetDuration":40,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":40,"overallStatus":73,"whyStopped":40,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":40},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,14,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"1","EXPERIMENTAL","MK0518 200 mg",[13],"Drug: Comparator: MK0518",{"label":15,"type":10,"description":16,"interventionNames":17},"2","MK0518 400 mg",[18],"Drug: MK0518",{"label":20,"type":10,"description":21,"interventionNames":22},"3","MK0518 600 mg",[18],{"label":24,"type":25,"description":26,"interventionNames":27},"4","PLACEBO_COMPARATOR","Placebo",[28],"Drug: Placebo",[30,37,41,44],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"DRUG","Comparator: MK0518","MK0518 oral tablets 200 mg b.i.d, for 24 weeks",[9],[36],"MK0518",{"type":31,"name":36,"description":38,"armGroupLabels":39,"otherNames":40},"MK0518 oral tablets 400 mg b.i.d, for 24 weeks",[15],null,{"type":31,"name":36,"description":42,"armGroupLabels":43,"otherNames":40},"MK0518 oral tablets 600 mg b.i.d, for 24 weeks",[20],{"type":31,"name":26,"description":45,"armGroupLabels":46,"otherNames":40},"Placebo to MK0518, oral tablet b.i.d, for 24 weeks",[24],[48],{"name":49,"affiliation":5,"role":50},"Medical Monitor","STUDY_DIRECTOR",{"type":52,"investigatorFullName":40,"investigatorTitle":40,"investigatorAffiliation":40,"oldNameTitle":40,"oldOrganization":40},"SPONSOR","100065601","phase-2-safety-and-efficacy-of-an-investigational-drug-in-human-immunodeficiency-virus-hiv-infected-patients-failing-current-antiretroviral-therapies-0518-005completed-100065601",true,"NCT00105157","Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)","Multicenter Study to Evaluate the Safety and Efficacy of MK0518 in Combination With An Optimized Background Therapy (OBT), Versus OBT Alone, in HIV-Infected Patients With Documented Resistance","Inclusion Criteria:\n\n* Patient must be HIV positive with Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) values that are within ranges required by the study\n* Patient must be currently on antiretroviral therapy (ART)\n\nExclusion Criteria:\n\n* Patient less than 18 years of age\n* Additional exclusion criteria will be discussed and identified by the study doctor",false,"ALL","18 Years",{"count":64,"type":65},179,"ACTUAL","INTERVENTIONAL",[68],"PHASE2","This study will investigate the safety and efficacy of different doses of an investigational drug (MK0518) as a therapy for HIV-infected patients failing current antiretroviral therapies.",[71,72],"HIV Infections","Acquired Immunodeficiency Syndrome","COMPLETED","2015-12-03",{"date":76,"type":77},"2015-12-04","ESTIMATED",{"date":79,"type":40},"2005-03",{"date":81,"type":65},"2009-07",{"name":5,"class":6}]